All In Biotech

Drug Trial Radar · NCT07436949

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-Blind, placebo-controlled, Single and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with or without Asthma.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

  • BBT002Drug

    BBT002 will be administered.

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following single and multiple administration of BBT002Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  2. Number of participants with change in vital sign measurements following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  3. Number of participants with change in physical examination following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  4. Number of participants with change in Laboratory assessmentsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  5. Number of participants with change in 12-lead ECG readingsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • People's Hospital of Peking University

    Beijing, Beijing Municipality, China · Recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Hospital of Shandong Province

    Jinan, Shandong, China · Recruiting

  • Qingdao University Hospital

    Qingdao, Shandong, China · Recruiting

  • The Affiliated Yuhuangding Hospital of Qingdao University

    Yantai, Shandong, China · Recruiting

  • Zibo Hospital of Shandong University

    Zibo, Shandong, China · Recruiting

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • The Second Hospital of Chengdu City

    Chengdu, Sichuang, China · Recruiting

  • Zhejiang People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.